Literature DB >> 8819096

Age-related tyrosine-specific protein phosphorylation defect in human T lymphocytes activated through CD3, CD4, CD8 or the IL-2 receptor.

R A Quadri1, O Plastre, M A Phelouzat, A Arbogast, J J Proust.   

Abstract

Although transmembrane signaling defect has been recognized as one of the major functional alterations involved in immune senescence, its biochemical nature as well as its precise molecular localization are still unknown. The available data indicate that an early step in the signaling cascade may be affected during the aging process. Because protein tyrosine kinases (PTK) are ubiquitously implicated in the initiation of physiological signals, they appear as prime candidates for age-related changes. The present investigation examined the effect of age on the activity of PTK associated with CD3, CD4, CD8 or the IL-2 receptor (IL-2R) in human T lymphocytes. By comparison with cells derived from young individuals, anti-CD3-activated T lymphocytes from elderly donors were more susceptible to herbimycin A, a PTK inhibitor known to prevent signal transduction by the T cell antigen receptor. This increased sensitivity of cells from senescent organisms to PTK inhibitors is most likely related to a lesser PTK activity since a significant decrease in the tyrosine phosphorylation of particular endogenous substrates was observed as a consequence of either CD3, CD4, CD8 or IL-2R activation. However, no age-related difference in tyrosine phosphorylation could be demonstrated when T cells were activated by pervanadate, a pharmacological activator of PTK. These results suggest that the intrinsic activity of the enzymes is preserved and that the age-associated defect in PTK activation occurs as a consequence of an upstream biochemical alteration. The defect in PTK activation could be the primary cause for the dysfunction of various components of the signaling cascade observed during the course of aging.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8819096     DOI: 10.1016/0047-6374(96)01715-0

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  7 in total

Review 1.  Thymic involution in aging.

Authors:  R Aspinall; D Andrew
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

2.  Telomere length measurement and determination of immunosenescence-related markers (CD28, CD45RO, CD45RA, interferon-gamma and interleukin-4) in skin-homing T cells expressing the cutaneous lymphocyte antigen: indication of a non-ageing T-cell subset.

Authors:  Karsten Neuber; Saskia Schmidt; Andrea Mensch
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

3.  Antioxidant micronutrients improve intrinsic and UV-induced apoptosis of human lymphocytes particularly in elderly people.

Authors:  A G Ma; S Ge; M Zhang; X X Shi; E G Schouten; F J Kok; Y Y Sun; X X Han
Journal:  J Nutr Health Aging       Date:  2011-12       Impact factor: 4.075

4.  Impact of aging: sporadic, and genetic risk factors on vulnerability to apoptosis in Alzheimer's disease.

Authors:  Katharina Schindowski; Tilmann Kratzsch; Jürgen Peters; Barbara Steiner; Silke Leutner; Natalie Touchet; Konrad Maurer; Christian Czech; Laurent Pradier; Lutz Frölich; Walter E Müller; Anne Eckert
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

5.  Alterations of T cell activation signalling and cytokine production by postmenopausal estrogen levels.

Authors:  Lowell T Ku; Cicek Gercel-Taylor; Steven T Nakajima; Douglas D Taylor
Journal:  Immun Ageing       Date:  2009-03-05       Impact factor: 6.400

Review 6.  Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing - a biochemical paradigm for the ageing immune system.

Authors:  Tamàs Fülöp; Anis Larbi; Gilles Dupuis; Graham Pawelec
Journal:  Arthritis Res Ther       Date:  2003-10-16       Impact factor: 5.156

Review 7.  Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?

Authors:  Jon Hazeldine; Janet M Lord
Journal:  Front Immunol       Date:  2020-10-06       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.